ABCL-406 Real-World Sequential Use of CD19-Directed Therapies for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab Preceding Chimeric Antigen Receptor T-Cell (CAR-T) Therapy

Autor: Epperla, Narendranath, Nastoupil, Loretta J., Feinberg, Bruce, Galvin, John, Pathak, Prathamesh, Amoloja, Theresa, Gentile, Danielle, Saverno, Kim
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S477-S477
Databáze: ScienceDirect
Externí odkaz: